35,000 Pounds Of Unlicensed Medicine Found In Car Boot
More than £35,000 of unlicensed erectile dysfunction medicine was seized in Sutton Coldfield yesterday as part of a covert investigation undertaken by the Medicines and Healthcare products Regulatory Agency (MHRA). A 60-year-old man was arrested for possession with intent to supply the medicines which included Kamagra, Savitra and Apcalis, all unlicensed Indian products.
Sunday, September 20, 2009
Saturday, September 19, 2009
Mayo Clinic Researchers Lead National Clinical Trial Testing New Treatment For Chronic, Severe Indigestion
Could medicines used for depression also treat chronic, severe indigestion? Scientists at Mayo Clinic suspect they can and, backed by funding from the National Institutes of Health (NIH), they are testing that premise in a nationwide clinical trial. "Nerve cells are found throughout the body, and just as their dysfunction in the brain can cause depression, we suspect overly sensitive nerves in the gut can produce this very uncomfortable indigestion," says Nicholas Talley, M.D., Ph. More at...
Friday, September 18, 2009
Metabolomics Used To Identify The Mechanism Of Action Of An Anti-Cancer Drug
Metabolomics Used To Identify The Mechanism Of Action Of An Anti-Cancer Drug
Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published identifying the mechanism of action of the anti-cancer drug GMX1778. Co-authored by scientists at Gemin X Pharmaceuticals and Metabolon, the paper "The Small Molecule GMX1778 is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in NAPRT1-Deficient Tumors" appears online ahead of print in Molecular and Cellular Biology.
Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published identifying the mechanism of action of the anti-cancer drug GMX1778. Co-authored by scientists at Gemin X Pharmaceuticals and Metabolon, the paper "The Small Molecule GMX1778 is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in NAPRT1-Deficient Tumors" appears online ahead of print in Molecular and Cellular Biology.
Subscribe to:
Posts (Atom)